OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study
evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the
treatment of inflammation and pain following cataract surgery. The primary objective is to
evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is
to evaluate the optimal dosing frequency (once a day [QD] or twice a day [BID]).